Catalogue number C100002
Chemical nameCycloart-23-ene-3,25-diol
CAS Number14599-48-5
SynonymsCycloart-23-ene-3b,25-diol; 9,19-Cyclo-9b-lanost-23-ene-3b,25-diol (7CI,8CI); 23-Dehydro-3b,25-dihydroxycycloartane;9,19-Cyclolanost-23-ene-3b,25-diol
Molecular WeightC30H50O2
Physical DescriptionCryst.
SolventChloroform, Dichloromethane,DMSO
StorageStored at 2-8°C, Protected from air and light, refrigerate or freeze

Cycloart-23-ene-3,25-diol was tested for anti-inflammatory activity using the cyclooxygenase assays (COX-1 and COX-2), anti-cholinesterase activity using the microplate assay and investigated for potential mutagenic effects using the Ames test. In the cyclooxygenase assays, cycloart-23-ene-3,25-diol showed inhibitory activity against COX-2 (80%) at a concentration of 100 uM (IC50 was 40 uM). At the same concentration, the compound showed weak activity against COX-1 (56%) with an IC50 value of 97 uM. In the anti-cholinesterase test, the compound had a weak inhibitory effect against acetylcholinesterase (53%) when tested at a concentration of 0.4 mM. No potential mutagenic effects were observed in the Salmonella microsome assay (TA 98).

Cycloart-23-ene-3,25-diol has ability to protect vital organs from the toxic effects persuaded in diabetic conditions in streptozotocin- nicotinamide induced diabetic mice. Cycloart-23-ene-3,25-diol treated diabetic mice showed minimum neuronal degeneration, which confirmed their protective activity against streptozotocin induced toxicity. Further molecular and cellular level study should be performed to understand the exact mechanism of Cycloart-23-ene-3,25-diol which may lead to development of new antidiabetic agent.

Both glybenclamide and Cycloart-23-ene-3,25-diol increased serum and pancreatic insulin. Glycosylated haemoglobin, serum cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, globulin, bilirubin, lactate dehydrogenase, urea and uric acid were decreased significantly after Cycloart-23-ene-3,25-diol treatment. Cycloart-23-ene-3,25-diol treatment decreased liver malondialdehyde but increased superoxidase dismutase and reduced glutathione. Histologically, focal necrosis was observed in the diabetic mouse pancreata but was less obvious in treated groups. The mechanism of Cycloart-23-ene-3,25-diol appears to be due to increased pancreatic insulin secretion and antioxidant activity.

References1. Natural Product Research, 2003, 17(5), 375-380.
2. Eur. J. Pharmacol., 2010, 632(1-3), 103-109.
3. South African Journal of Botany, 2007, 73(3), 366-371.
4. Asian Pacific Journal of Tropical Biomedicine (2011), 1-5.
  Fill your Email(  
After Receiving
The packaging of the product may have turned upside down during transportation, resulting in the product adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Featured Products
C104530Ginsenoside Rh4$294.00/10mg
C101411Ganoderol B$294.00/5mg
C1042773-O-Caffeoylquinic acid methyl ester$454.00/5mg
5mg$440.005% OFF
10mg$748.008% OFF
25mg$1272.0015% OFF
Orders by E-mail
Orders can be placed by Emails. All orders received will be shipped in the next day if the stock is available.

To place an order, please provide the following information.

1) Your name and telephone number
2) Purchase order number
3) Product number, package size, description, and quantity
4) Shipping and billing addresses

Sent to your order to our email:
Discount Request
If you have any questions about discounts or dealer discount, please send us a message. We will be glad to help.
Go directly to Coompo product type beginning with
  • Contact Us

  • Email:
  • Tel: +86-27-84396673
  • Building B, No.77 Chuangye Rd,
  • Wuhan Economic and Technological Development Zone,
  • Hubei 430056, PRC
  • ©2013-2017 Coompo  |  All rights reserved.